Each predicted quartile was plotted against the actual one and the number of subjects classified within each quartile gave an indication on the effectiveness of the prediction.
The CEAF (Fig. 2) shows that the probability of treat all being cost-effective, given a cost-effectiveness threshold value of £20,000, is 45%.
Cost-effectiveness analysis gave an incremental cost of MRI screening of $46929595% CI: 3084, 7910) per participant, with 0.092 QALYs gained (95% CI: -0.027, 0.190), resulting in a mean ICER of $50,911/QALY (Table 4).
Given a similar effectiveness, a smaller cell number would be favorable in view of potential adverse reactions.
Given a discrete effectiveness (50% in the base case) the longer patients remain on therapy the greater the benefit and the fewer NNT and NNS required for a success.
Our economic analysis revealed that treating all CHC patients without testing for fibrosis stage was the most cost-effective strategy given a cost-effectiveness threshold of £20,000.
When discounted at 6%, IFNβ-1b was shown to reduce relapse by 1.52 per patient (over 5 years) giving a cost-effectiveness ratio of £28,700 (US$44,428) per relapse avoided.
Given a cost-effectiveness threshold of $83 000, it may be more efficient to screen unvaccinated women, more frequently than those women who were vaccinated during adolescents.
On the other hand, given a cost-effectiveness threshold on 50,000 € per QALY gained vaccination of boys and girls is estimated to be cost-effective.
The lifetime gain in Quality-Adjusted life Years (QALYs) was 0.00 038, giving a cost-effectiveness ratio of £321 000 which is highly unfavourable against the conventional willingness-to-pay threshold of £20 000 per QALY.
